ArticleFrontiers in medicine2025
Case Report: The first account of primary myeloid sarcoma of the testis combined with ipsilateral epididymal epithelioid hemangioendothelioma.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a 35-year-old male with primary myeloid sarcoma (MS) of the testis and concurrent ipsilateral epididymal epithelioid hemangioendothelioma (EHE)-an exceptionally rare combination. Myeloid sarcoma typically involves the skin and bone, but testicular involvement is rare, particularly as an isolated tumor without hematologic malignancy. This makes diagnosis challenging. Epithelioid hemangioendothelioma is a rare vascular tumor, typically found in the liver, lungs, and bones, and epididymal EHE is scarcely reported. The patient had a left testicular nodule for 6 months and experienced pain for 2 days. Ultrasound and MRI revealed abnormalities in the left testis and epididymis. Histopathological examination of the epididymal biopsy showed tumor cells with specific morphological features, and immunohistochemistry (IHC) indicated CD31(+), CD34(+), Fli-1(+), ERG(+), Ki-67(+5%+), along with WWTR1-CAMTA1 gene fusion by fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.